The US FDA Approves Biocon Biologics’ Jobevne (Biosimilar, Avastin)
Shots:
- The US FDA has approved Jobevne, a biosimilar version of Avastin (bevacizumab) for IV administration
- Approval was based on extensive data showing Jobevne is similar to Avastin in PK, safety, efficacy, structure, & function across clinical & analytical studies
- Jobevne (VEGF inhibitor) is marketed under the brand name Abevmy in the EU & Canada, with approvals granted in Feb & Nov 2021, respectively
Ref: Biocon Biologics | Image: Biocon Biologics
Related News:- Biocon Biologics Partners with Civica to extend access of Insulin Aspart in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
